6NQ.F BIOMED-LUBLIN WYT.SUR.
- Market cap
- EUR 43.0M
- P/E
- -
- P/B
- 1.64x
- ROE
- -10.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6NQ.F undervalued?
Graham numberThe Graham number of BIOMED-LUBLIN WYT.SUR. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BIOMED-LUBLIN WYT.SUR. fundamental analysis
No fundamental analysis for BIOMED-LUBLIN WYT.SUR. yet.
BIOMED-LUBLIN WYT.SUR. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BIOMED-LUBLIN WYT.SUR.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladde…
Full company profileBIOMED-LUBLIN WYT.SUR. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BIOMED-LUBLIN WYT.SUR. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 41.2M | 50.4M | 58.6M | 71.8M | 42.0M | 52.9M |
| Gross Profit | 22.7M | 27.9M | 35.2M | 44.3M | 23.6M | 29.3M |
| Operating Income | 6.56M | 9.26M | 8.65M | 12.5M | -13.1M | -2.53M |
| EBITDA | - | 16.2M | 9.13M | 12.7M | -19.3M | 8.86M |
| Net Income | 4.25M | 6.08M | 4.76M | 7.55M | -19.9M | -12.7M |
| EPS | 0.07 | 0.09 | 0.07 | 0.11 | -0.26 | -0.22 |
| Balance Sheet | ||||||
| Total Assets | 117M | 163M | 266M | 299M | 304M | 295M |
| Total Liabilities | 42.3M | 57.5M | 153M | 177M | 179M | 176M |
| Shareholders' Equity | 74.6M | 106M | 113M | 121M | 125M | 119M |
| Cash & Short-term Investments | 14.3M | 27.1M | 2.18M | 760K | 1.67M | 350K |
| Cash Flow | ||||||
| Operating Cash Flow | -3.28M | 2.95M | -5.35M | 14.8M | 11.8M | 12.6M |
| Capital Expenditure | 18.4M | 36.8M | 113M | 41.8M | 28.0M | 1.45M |
| Free Cash Flow | -21.7M | -33.8M | -5.35M | -27.0M | -16.2M | 11.3M |
| Ratios | ||||||
| ROE | 5.7% | 5.8% | 4.2% | 6.2% | -16.0% | -10.7% |
| ROA | 3.6% | 3.7% | 1.8% | 2.5% | -6.6% | -4.3% |
| Net Profit Margin | 10.3% | 12.1% | 8.1% | 10.5% | -47.4% | -24.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BIOMED-LUBLIN WYT.SUR. dividends
BIOMED-LUBLIN WYT.SUR. has not paid dividends in the last 5 fiscal years.
Who owns BIOMED-LUBLIN WYT.SUR.
- Insiders 43.87%
- Institutions 6.84%
- Public & others 49.30%
- Shares outstanding 76.0M
- Free float 48.6M
BIOMED-LUBLIN WYT.SUR. company profile
- Company name
- BIOMED-LUBLIN WYT.SUR.
- Ticker
- 6NQ.F
- ISIN
- PLBMDLB00018
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 214
- Fiscal year end
- December
- Address
- ul. Uniwersytecka 10, Lublin, Poland, 20-029
- Phone
- 48 81 533 8221
- Website
- synthaverse.com
About BIOMED-LUBLIN WYT.SUR.
Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anti-D 50 and GAMMA anti-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines. It also provides Distreptaza, a medication for chronic ovarian inflammation and hemorrhoidal disease; LAKCID, which is a lactobacillus probiotic drug; and pseudocholinoesteraza, which is a laboratory reagent. In addition, the company engages in the contract production of injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, and suppository forms of drugs. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. Synthaverse S.A. was founded in 1944 and is headquartered in Lublin, Poland.
BIOMED-LUBLIN WYT.SUR. management
5- Dr. Artur Chodkowski Ph.D.President of Management Board
- Mr. Dariusz Jan KucowiczMember of the Management Board for Finance
- Mr. Jakub WinklerChief Organizational & Legal Officer and Member of the Management Board
- Mr. Waldemar SierockiSecretary of Supervisory Board & Member of Supervisory Board
- Ms. Katarzyna KrukowoskaChief Accountant